AU1428499A - System for cardiac procedures - Google Patents

System for cardiac procedures Download PDF

Info

Publication number
AU1428499A
AU1428499A AU14284/99A AU1428499A AU1428499A AU 1428499 A AU1428499 A AU 1428499A AU 14284/99 A AU14284/99 A AU 14284/99A AU 1428499 A AU1428499 A AU 1428499A AU 1428499 A AU1428499 A AU 1428499A
Authority
AU
Australia
Prior art keywords
valve
catheter
patient
replacement valve
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU14284/99A
Other versions
AU714807B2 (en
Inventor
John H. Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heartport Inc
Original Assignee
Heartport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU60491/94A external-priority patent/AU699189B2/en
Application filed by Heartport Inc filed Critical Heartport Inc
Priority to AU14284/99A priority Critical patent/AU714807B2/en
Publication of AU1428499A publication Critical patent/AU1428499A/en
Application granted granted Critical
Publication of AU714807B2 publication Critical patent/AU714807B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Landscapes

  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Description

s~-~--8llr~i ari-s~--~-aQILn~.~ S F Ref: 346375D1
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATON FOR A STANDARD PATENT
ORIGINAL
Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Heartport, Inc.
200 Chesapeake Drive Redwood City California 94063 UNITED STATES OF AMERICA John H. Stevens Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia System for Cardiac Procedures r i I 'rI
I
o -c
I-
::r r :i The following statement is a full description of this invention, including the best method of performing it known to melus:a m t:(l gi cii
I-
SYSTEM FOR CARDIAC
PROCEDURES
FIELD OF THE
INVENTION
This invention relates to methods and systems for performing cardiac procedures and particularly endovascular cardiac procedures such as the placement of or the removal and replacement of heart valves.
7 BACKGROUND OF THE INVENTION There are two major categories of heart valve disease, namely, stenosis, which is an obstruction to forward blood flow caused by a heart valve, and regurgitation, which is the retrograde leakage of blood through a heart valve.
When it is necessary to repair or replace a Smalfunctioning heart valve within a patient, heretofore the repair or I replacement has been accomplished by a major open-heart surgical Sprocedure, requiring general anesthesia and full cardiopulmonary by-pass with complete cessation of cardiopulmonary activity. Such surgery usually includes about three weeks of hospitalization and months of t: 1 A4iMM, -b A_ i
B
I
:1.
:i 1 ns .i
:S
~I i ~1
-I~
:~I
:i;i Bt
.I
recuperation time for the patient. The average mortality rate with this type of procedure is about five to six percent, and the complication rate is substantially higher. Descriptions of open-heart procedures for replacing heart valves can be found in Gbonof theChest, Ed., David C. Sabision, Jr., Frank D. Spencer, 1990, Vol. II, Ch. 52, pp. 1566-1596, and Textbook of nervetnal Cardiolo, Eric J. Topol, 1990, Chs. 43-44, pp. 831-867.
Endovascular surgical procedures on the heart have been developed recently which, in contrast to open-heart surgical procedures, may have a reduced mortality rate, may require only local anesthesia, and may necessitate only a few days of hospitalization.
However, the range of applications of endovascular heart procedures other than those of the coronary arteries, such as angioplasty and atherectomy, has been limited.
15 Some progress has been made in developing endovascular procedures involving the heart valves. For example, for patients with severe stenotic valve disease, who are too compromised to tolerate open- heart surgery to replace the heart valve as described above, surgeons have attempted endovascular balloon aortic or mitral valvuloplasty. These procedures involve endovascularly advancing a balloon dilatation catheter into the patient's vascuiature until the balloon of the catheter is positioned between the valve leaflets and then inflating the balloon to split the commissures in a diseased valve with commissural fusion and to crack calcific plaques in a calcified stenotic valve. However, this method may provide only partial and temporary
;J
;r.
i,, ii i..ii I ;i- I i: ry 1. 3 relief for a patient with a stenotic valve. The rapid restenosis following balloon aortic valvuloplasty has led to virtual abandonment of this procedure as a treatment of the diseased aortic valve.
An endovascular treatment regimen for regurgitant heart valves, which involves valve supplantation, has been disclosed in the patent literature, but apparently the procedure has not been clinically practiced. In this procedure, it is conceived that an elongated catheter is used to insert a mechanical valve into the lumen of the aorta via entry through a distal artery, for example, the brachial or femoral artery. One such mechanical valve is described in U.S. Patent 4,056,854 (Boretos et that is designed to be positioned against the artery wall during forward flow, as compared to the mid-center position of the valve described in U.S. 3,671,979 (Moulopoulos). The valve positioned against the arterial wall is intended to reduce the stagnation of blood flow and consequent thrombus and emboli formation compared to a valve at midcenter position. The mechanical valves previously described require an elongated mounting catheter extending out of the arterial entry point to maintain the position of the valve in the descending aorta. These valves would be expected to present several problems. The valves do not S. SO provide a permanent or internalized system. Furthermore, since both involve a mechanical valve, which predisposes the patient to thrombus formation and emboli, long term anticoagulant therapy is required. A serious complication of long term anticoagulant therapy is intracranial 1 hemorrhage. Finally, the supplemental valve is placed downstream from 4 both the normal valve position and the coronary ostia, so normal heart and coronary artery hemodynamics are not restored.
The descriptive terms upstream and downstream, when used herein in relation to the patient's vasculature, refer to directions closer to and further from the heart, as applicable. The terms proximal and distal, when used herein in relation to instruments used in the procedure, refer to directions closer to and farther away from the operator performing the procedure.
SUMMARY OF THE INVENTION It is the object of the present invention to overcome or substantially ameliorate at least one of the above disadvantages.
There is disclosed herein a system introducing a replacement valve comprising: a replacement valve having a portion which inverts from a first position to a second position, the replacement valve permitting flow in a direction and preventing flow in the other direction when in the second position; a valve delivery device for delivering the replacement valve, the replacement valve being mounted to the valve delivery device in the first position, the replacement valve being inverted from the first position to the second position after introduction into the patient.
A preferred endovascular system includes an elongated catheter having proximal and distal ends and an occluding member on a distal portion of the catheter adapted to occlude a patient's ascending aorta. The catheter preferably has an inner lumen extending within the catheter to a port in the distal end of the catheter. The preferred catheter is adapted to be inserted into the patient's arterial system (e.g.
a "r
:I
through the femoral or brachial arteries) and to be advancea to tne ascending aorta where the occluding member i- expanded to occlude the aorta at that location. In so doing the left ventricle of the heart and an upstream portion of the ascending aorta are separated from the rest of the patient's arterial system. This catheter thus constitutes an endovascularly inserted, internal vascular clamp, similar in function to the external "cross-clamp" used in open-surgical procedures. The internal clamp is less traumatic to the clamped vessel, and provides a lumen or working channel through which instruments or fluids may be passed into or withdrawn from the area upstream of the end of the distal end of the clamp. The occluding member on the elongated catheter should be dimensioned so that upon expansion it will be located downstream from the ostia for the coronary arteries and upstream from the brachiocephalic artery so as to avoid blocking these arteries. In one presently preferred embodiment, the inner lumen of the occluding catheter is dimensioned to i allow for the passage therethrough of instruments for the performing the cardiac procedure.
Also included with the system is a cardiopulmonary by-pass system which withdraws blood from the patient's venous 20 system, e.g. the femoral or jugular vein, removes CO2 from and adds oxygen to the withdrawn blood, and then returns the oxygenated blood to the patient's arterial system, e.g. the femoral or brachial artery. The system is also provided with means to deliver a fluid containing cardioplegic material an aqueous solution of KCI and/or magnesium 6 procaine and the like) through the coronary arteries so as to paralyze the myocardium.
It is also preferred to depressurize the left atrium by venting the left atrium via a catheter placed in the pulmonary artery. This catheter may actually occlude the pulmonary artery to further prevent blood from flowing to the lungs. With the heart paralyzed, the expandable member of the aortic catheter expanded within the ascending aorta, and the cardiopulmonary by-pass operating, the heart is prepared for a cardiac procedure. While a particularly attractive feature of the invention is that it prepares the heart for an endovascular procedure, the invention can also be used to prepare the heart for conventional openheart surgery via a thoracotomy. It should also be noted that, if during an endovascular cardiac procedure in accordance with the invention it becomes necessary to perform an open-heart procedure, the patient is 15 already fully prepared for the open-heart procedure. All that i. necessary ,is to perform a thoracotomy to expose the patient's heart for the conventional surgical procedure.
in a presently preferred embodiment of the invention directed to endovascular cardiac procedures, the occlusion catheter is adapted to deliver instruments to be used during the procedures such as the removal of an in-place aortic valve, the insertion and placement of a new valve, and the securing of the new valve at the desired location. In S these procedures, the expanded expadable member on the distal end of the occlusion catheter firmly secures the distal end of the catheter within r the aorta to allow for the accurate guidance of instruments to be used during the procedure.
By partitioning the arterial system with the elongated aortic catheter in this manner, a body of clear fluid can be maintained in the aortic region upstream from the expanded distal end of the aortic catheter to facilitate the imaging, e.g. angioscopic observation, of the cardiac procedure- A continual flow of clear fluid may be directed to the surgical field in order to maintain fluid clarity sufficient for imaging the site during the procedure. The pressure of the body of irrigation fluid at the surgical site can be maintained at a level equal to or higher than the fluid pressure in the patient's left atrium to prevent the intrusion of blood from the left atrium into the left ventricle, which can interfere with the imaging. The temperature of the irrigating fluid should be about 40 C in order to reduce myocardial oxygen demand.
15 In order to deliver cardioplegic fluids to the myocardium, it is presently preferred to carry out retrograde perfusion of the coronary circulation. Using this technique, a physician will percutaneously introduce a catheter through a major vein, e.g. the right internal jugular vein, and advance the catheter in the venous system until 20 the distal end of the catheter extends into the coronary sinus through the discharge opening thereof in the right atrium. Preferably, the catheter has an inflatable balloon on the distal end thereof, such as shown in U.S.
Patent 4,689,041, U.S. Patent 4,943,277, and U.S. Patent 5,021,045, which are incorporated herein by reference. When inflated, the balloon blocks the discharge opening of the coronary sinus to preclude loss of r rr rr r i
I
II
~i e 4 1 i
;I
.r
I
i-i: :6 ;i: ,ir i; r: Is ii, 2_; 1 cardioplegic fluid therefrom. With the discharge opening of the coronary sinus blocked off, aqueous liquid or other fluid containing cardioplegic material is delivered through the catheter into the coronary sinus at sufficient pressure so that it passes into the myocardium via the capillary bed between the venous and arterial systems therein so as to paralyze the entire myocardium. Typically, cardioplegic solution pressure within the coronary sinus should be less than 100 mm Hg to avoid tissue damage. After passing through the myocardium, the cardioplegic liquid will pass through the coronary arteries in a retrograde fashion to be discharged through the coronary ostia into the upstream portion of the ascending aorta. The cardioplegic fluid which discharges from the coronary ostia will initially be very opaque due to blood being flushed out of the coronary circulation, but eventually the fluid will become clear and may be conveniently used to form and maintain the body of clear fluid at 15 the surgical site to facilitate the imaging thereof during the procedure. In some instances, cardioplegic liquid may instead be delivered through the coronary arteries in an antegrade fashion, either via catheters placed through the coronary ostia into the coronary arteries or by delivery via the aortic catheter directly into the aortic root.
20 The left atrium is preferably decompressed by one of two methods. The first involves a catheter passing into the puimonary trunk. The catheter described is advanced through the patient's venous system, e.g. through the right internal jugular vein, through the right atrium and the right ventricle, and into the pulmonary trunk. This catheter can vent fluid from the pulmonary trunk via an inner lumen if -1_ n f~a
P'-
-r; 51~ i;-
-I
10 10 extending from its distal port to a port in its proximal end located outside the patient. It may be advantageous to nave an infiatabie member located at the distal end of the ventilation catheter. The inflatable member is dimensioned so that upon inflation it will block the pulmonary trunk while simultaneously venting the trunk through the inner lumen of the catheter, which extends through the catheter from a port in its distal end to a port in its proximal end located outside of the patient.
In an alternative method, as described in U.S. Patent 4,889,137 (Kolobow) which is incorporated herein by reference, a catheter is advanced in essentially the same manner as that described above until the distal end is within the pulmonary trunk. As described in this patent, springs or other means are provided on the exterior of the catheter at the locations where the catheter will extend through the pulmonary and tricuspid valves in order to hold the valves at least partially open and thereby vent the pulmonary artery and decompress the left atrium.
~i~j i: ~l-mzct -i r b .r .r 1 s The occluding aortic catheter with an expandable occluding member on the distal end, coupled with cardiopulmonary bypass, cardioplegia, and decompression of the left atrium, provides for a unique intravascular approach to a wide variety of cardiac procedures, an approach which does not require invasive thoracic or abdominal surgery.
Moreover, as mentioned, the system may even be employed in conventional open-heart procedures. In addition, the system may be used in minimally invasive cardiac procedures under thoracoscopic guidance, working through incisions in the patient's chest from outside the patient's I F r/-
,.I
body. In these instances the occluding catheter need not have an inner lumen for delivery of fluids and the like. These and other advantages of the invention will become more apparent from the following detailed description of the invention when taken in conjunction with the accompanying exemplary drawings.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 schematically illustrates a cardiac access system embodying features of the invention.
Figure 2 is an enlarged view, partially in section, of the occluding catheter shown in Fig. 1 disposed within the ascending S|aorta.
Fig. 3 is a transverse cross-sectional view of the 1.5 occluding catheter shown in Fig. 2 taken along the lines 3-3.
ji Fig. 4 is an enlarged view, partially in section, of the :cardioplegia delivery catheter and the pulmonary venting catheter shown in Fig. 1.
o i t Fig. 5 is an elevational view, partially in section, of the occluding catheter shown in Fig. 2 schematically illustrating the removal of an aortic heart valve.
Fig. 6 schematically illustrates the introduction of a prosthetic valve into the region of the ascending aorta from which the original heart valve had been removed.
t -3~-^F*~gCCm~ ii L2::20 c co i 25 11 Fig. 7 schematically illustrates securing a mounting skirt on the prosthetic valve to the wall of the ascending aorta.
Fig. 8 schematically illustrates securing the upper extensions of the valve to the aortic wall.
Fig. 9 schematically illustrates an alternate means for removing a heart valve.
Fig. 10 is an enlarged perspective view of the cutting member of the catheter shown in Fig. 9.
Fig. 11 schematically illustrates another alternate means for removing a heart valve.
Figs. 12 and 13 schematically illustrate an alternate embodiment of a valve introducing device and the method of discharging a prosthetic or replacement valve.
Fig. 14 schematically represents in an elevational view a prosthetic heart valve.
Fig. 15 is a top view of the prosthetic heart valve shown in Fig. 14.
DETAILED DESCRIPTION OF THE INVENTION Reference is made to Fig. 1 which schematically illustrates the overall cardiac accessing system of the invention and the individual components thereof. The accessing system includes an elongated aortic occlusion or delivery catheter 10 which has an expandable member 11 on a distal portion of the catheter which, when Is
S-
;Lj, 7 12 inflated as shown, occludes the ascending aorta 12 to separate the left ventricle 13 and upstream portion of the ascending aor:i from the rest of the patient's arterial system and securely positions the distal end of the catheter within the ascending aorta. A cardiopulmonary by-pass system 18 removes venous blood from the femoral vein 16 through the blood withdrawal catheter 17 as shown, removes CO, from the blood, oxygenates the blood, and then returns the oxygenated blood to the patient's femoral artery 15 through the return catheter 19 at sufficient pressure so as to flow throughout the patient's arterial system except for the portion blocked by the expanded occluding member 11 on the aortic occluding catheter 10. A retrograde cardioplegia balloon catheter 20 is disposed within the patient's venous system with the distal end of the catheter extending into the coronary sinus 21 (shown in Fig. 4) to deliver a fluid containing cardioplegic agents to the myocardium in a retrograde 15 manner through the patient's coronary venous system to paralyze the entire myocardium.
The elongated occluding catheter 10 extends through the descending aorta to the left femoral artery 23 and out of the patient through a cut down 24. The proximal extremity 25 of the catheter which extends out of the patient is provided with a multi-arm adapter 26 S....with one arm 27 adapted to receive an inflation device 28. The adapter 4t 26 is also provided with a second arm 30 with main access port 31 S through which passes instruments, a valve prosthesis, an angioscope, 4X i irrigation fluid and the like. A third arm 32 connected to by-pass line 33 S 25 is provided to direct blood, irrigation fluid, and the like to or from the i Mpg, 13 system. A suitable valve 34 is provided to open and close the by-pass line 33 and direct the fluid passing through the by-pass line to a discharge line 35 or a line 36 to a blood filter and recovery unit 37. A return line 38 may be provided to return any filtered blood, which will be described hereinafter, to the cardiopulmonary by-pass system 18 or other blood conservation system.
SThe details of the aortic occlusion catheter 10 and the disposition of the distal extremity thereof within the aorta are best illustrated in Figs. 2 and 3. As indicated, the catheter 10 includes an elongated catheter shaft 39 which has a first inner lumen 40 in fluid communication with the main access port 31 in the second arm of the adapter 26 and is adapted to facilitate the passage of instruments, a valve prosthesis, an angioscope, irrigation fluid, and the like therethrough and out the distal port 41 in the distal end thereof. A supporting coil 42 15 may be provided in the distal portion of the first inner lumen 40 to prevent the catheter shaft 39 from kinking as it is advanced through the aortic arch. The shaft 39 is also provided with a second inner lumen 43 which is in fluid communication with the interior of the occluding balloon 11.
20 A retrograde cardioplegia balloon catheter 20, which is shown in more detail in Fig. 4; is introduced into the patient's venous system through the right internal jugular vein 44 and is advanced through °the right atrium 45 and into the coronary sinus 21 through the coronary sinus discharge opening 46 in the right atrium. The retrograde catheter 20 is provided with a balloon 47 on a distal portion of the catheter 14 which is adapted to occlude the coronary sinus 21 when inflated.
A
!iquid containing a cardioplegic agent, e.g. an aqueous KCI solution, is introduced into the proximal end 48 of the catheter 20, which extends outside of the patient, under sufficient pressure so that the fluid containing the cardioplegic agent can be forced to pass through the coronary sinus 21, through the capillary beds (not shown) in the patient's myocardium, through the coronary arteries 50 and 51 and ostia 52 and 53 associated with the-respective coronary arteries into the blocked off portion of the ascending aorta 12 as shown.
A pulmonary venting catheter 54 is also shown in Fig.
4 disposed within the right internal jugular vein 44 and extending through the right atrium 45 and right ventricle 55 into the pulmonary trunk 56.
The catheter 54 passes through tricuspid valve 57 and pulmonary valve 58. An inflatable occluding balloon 60 may be provided as shown on a distal portion of the pulmonary venting catheter 54 which is inflated to occlude the pulmonary trunk 56 as shown. The pulmonary venting Scatheter 54 has a first inner lumen 61 which extends from the distal end of the catheter to the proximal end of the catheter which vents fluid from Sthe pulmonary trunk 56 to outside the patient's body either for discharge 20 or for passage to the blood recovery unit and thereby decompresses the left atrium 14 through the pulmonary capillary beds (not shown). The t catheter 54 has a second inner lumen 62 which is adapted to direct V C inflation fluid to the interior of the inflatable balloon I To set up the cardiac access system, the patient is i initially placed under light general anesthesia. The withdrawal catheter ~e 17 and the return catheter 19 of the cardiopulmonary by-pass system 18 are percutaneously introduced into the right femoral vein 16 and the right femoral artery 15, respectively. An incision 24 is also made in the left groin to expose the left femoral artery 23 and the aortic occluding catheter 10 is inserted into the left femoral artery through an incision therein and advanced upstream until the balloon 11 on the distal end of the occluding catheter 10 is properly positioned in the ascending aorta 12. Note that by-pass could similarly be established in the left groin and the aortic occlusion catheter put into the right femoral artery. The retrograde perfusion catheter 20 is percutaneously inserted by a suitable means such as the Seldinger technique into the right interior jugular vein 44 and advanced into the right atrium 45 and guided through the discharge opening 46 into the coronary sinus 21.
The pulmonary venting catheter 54 is advanced through the right internal jugular vein 44, the right atrium 45, and right I ventricle 55, and into the pulmonary trunk 56. The occluding balloon may be inflated if necessary by inflation with fluid passing through the lumen 62 to block the pulmonary trunk 56 and vent blood therein through i the lumen 61 where it is discharged through the proximal end of the 0 catheter which extends outside of the patient. The venting of the Spulmonary trunk 56 results in the decompressing of the left atrium 14. In the alternative, the venting catheter 54 may be provided with means on the exterior thereof, such as expanded coils as described in U.S. Patent 4,889,137 (Kolobow), which hold open the tricuspid and pulmonary valves and perform the same function of decompressing the left atrium.
-4i See also the article written by F. Rossi et al in the Journal of Thoracic Cardiovascular Surgery, 1990;100:914-921, entitled "Long-Term Cardiopulmonary Bypass By Peripheral Cannulation In A Model Of Total Heart Failure", which is incorporated herein in its entirety by reference.
The operation of the cardiopulmonary by-pass unit 18 is initiated to withdraw blood from the femoral vein 16 through catheter 17, remove
CO
2 from and add oxygen to the withdrawn blood and then pump the oxygenated blood through the return catheter 19 to the right femoral artery 15. The balloon 11 may then be inflated to occlude the ascending aorta 12, causing the blood pumped out of the left ventricle (until the heart stops beating due to the cardioplegic fluid as discussed hereinafter) to flow through the discharge port 41 into the first inner lumen 40 of the occluding catheter. The blood flows through the inner lumen 40 and out the third arm 32 of the adapter 26 into the by-pass line 15 33 and then into the blood filter and blood recovery unit 37 through the valve 34 and line 36. For blood and irrigation fluids containing debris and -the like, the position of the valve 34 may be changed to direct the fluid through the discharge line The balloon 47 on the distal extremity of the 20 retroperfusion catheter 20 is inflated to occlude the coronary sinus 21 to prevent fluid loss through the discharge opening 46 into the right atrium 45. A liquid containing a cardioplegic agent such as KCI is directed through the catheter 20 into the coronary sinus 21 and the pressure of the cardioplegic fluid within the coronary sinus 21 is maintained sufficiently high 40 mm Hg) so that the cardioplegic fluid will pass 7 sa '*1 Aii 4i
L:
17 though the coronary veins, crossing the capillary beds to the coronary arteries 50 and 51 and out the ostia 52 and 53. However, cardioplegic fluid level is not increased far above 100 mm Hg. Once the cardioplegic fluid passes through the capillary beds in the myocardium, the heart very quickly stops beating. At that point the myocardium is paralyzed and has very little demand for oxygen and can be maintained in this state for long periods of time with minimal damage.
With the cardiopulmonary by-pass system in operation, the heart completely paralyzed and not pumping, the left atrium decompressed and the ascending aorta blocked by the inflated balloon 11 on the occluding catheter 10, the heart is appropriately prepared for a cardiac procedure.
Inflation of the inflatable member 11 on the distal end of the delivery catheter 10 fixes the distal end of the occluding catheter 5 10 within the ascending aorta 12 and isolates the left ventricle 13 and the upstream portion of the ascending aorta from the rest of the arterial system downstream from the inflatable member. The passage of any debris or emboli, solid or gaseous, generated during a cardiovascular procedure to regions downstream from the site would be precluded by the inflated balloon 11. Fluid containing debris or emboli can be removed from the region between the aortic valve and the occluding balloon 11 through the inner lumen 40of catheter 10. A clear, compatible fluid, e.g.
an aqueous based fluid such as saline delivered through the inner lumen or the cardioplegic fluid discharging from the coronary ostia 52 and 53, may be maintained in the region wherein the cardiovascular procedure ,y.
n~ P~ is to be performed to facilitate use of an angioscope or other imaging means that allows for direct observation of the cardiac procedure.
Preferably, the fluid pressure in the left ventricle 13 is maintained sufficiently higher than that in the left atrium to prevent blood from the left atrium from seeping into the left ventricle and interfering with the observation of the procedure. The inner lumen 40 is dimensioned to allow for the passage of instruments used during the cardiac procedure such as a tissue cutter, an angioscope, and tubes used for infusing irrigation fluid and for aspirating debris, thrombus and the like, and for the introduction of a prosthetic device, such as a heart valve.
The cardiac accessing system of the invention is particularly useful in the removal of the aortic heart valve and replacement thereof with a prosthetic heart valve which is illustrated in Figs. 5 through 8. As shown in Fig. 5, a tissue cutter 65 is inserted into 15 the patient through the inner lumen 40 of the occluding catheter 10 and advanced therein to the site of the aortic valve 66 which is to be removed. An angioscope 67 is likewise advanced through the inner lumen until the distal end thereof extends out of the distal end of the occluding catheter 10. At least one of the cutting blades 68 and 69 on 20 the tissue cutter 65 is actuated from the proximal end thereof which extends out of the second arm 30 of the adapter 26 on the proximal end of the catheter 10. The guidance and operation of the cutter 65 is controlled by the physician or other operator while observing the cutter through the angioscope 67. Due to its size and condition, the aortic valve 66 will usually have to be cut into smaller sections, such as section
I
I
I I r I r I I I I r Ir Ir r 1 'Q1,.
i i i:.
rii
I-
ii I:r;
~I
~i~q(e~C~g -s:i L ~1 ~"I~~L"ss"~-plc as shown, so that it will fit within the inner lumen 40 of the occluding catheter 10 in order to remove the valve material from the patient.
Preferably, forceps 71 or other suitable grasping means are employed to hold onto the aortic valve sections as they are severed by the cutting means 65 to ensure that the valve sections are accurately severed from the site with little or no damage to the underlying tissue of the ascending aorta and removed through the inner lumen 40. The cutting means may have to be withdrawn from the occluding catheter 10 before large severed portions of the aortic valve 66 can be removed by forceps 71.
During the procedure a continuous flow of clear liquid, such as the clear cardioplegic fluid exiting the ostia 52 and 53 and/or fluid being infused via the clamp 10 or an angioscope 67, is maintained to facilitate the observation of the region by the operator using the angioscope 67. After S the valve 66 has been severed and removed from the region, the instruments used for this particular procedure are withdrawn from the patient through the inner lumen 40 of the occluding catheter 10. Instead of or in addition to mechanical cutting means, laser, electrosurgery, or other cutting methods may be employed in the valve removal procedure.
Direct observation of the placement of the cutting device 65 by suitable imaging means such as an angioscope 67 will ensure accurate positioning of the cutter blades 68 and 69 against the aortic valve to more effectively sever the valve 66 with little or no damage to the supporting aortic tissue. Aortic damage might interfere with the placement of a replacement valve 72 at the site. The precision of the valve removal and replacement is important to the success of o
I
I is r r r
I
HE.~
ntlu.
11-WIM own endovascular valve replacement. There are several imaging techniques preqentVl available, in addition to the angioscopic technique described, which provide complementary options to assure this precision, namely 1) transesophageal echocardiography; 2) intravascular ultrasound passed through the inner lumen of the delivery catheter 10; 3) intravascular ultrasound or angioscopy passed intravascularly -:ia the venous system through the intra-atrial septum, across the mitral valve, and into the left ventricle; and 4) fluoroscopy. Note that an angioscope within the left ventricle would provide both the added benefit of allowing constant high definition imaging of the entire procedure and high-flow irrigation.
After the heart valve 66 is removed, a replacement valve 72 is then advanced through the inner lumen 40 of the occluding catheter 10 as shown in Fig. 6. The valve 72 is preferably a bioprosthetic valve such as xenograft valve. Porcine glutaraldehyde 15 preserved valves are quite suitable because, as previously mentioned, they are readily accessible, they are storable, and they are available in a variety of sizes. The replacement valve 72, which is shown in Fig. 6 in an inverted and folded condition, has a Dacron skirt 73 secured to the lower rim of the natural porcine valve to facilitate securing the replacement valve to the wall of ascending aorta 12 at or near to the site from which the original aortic valve 66 was removed. The folded and inverted replacement valve 72 is disposed within the expanded end 74 of valve delivery catheter 75 so that the valve 72 can be advanced through the occluding catheter 10. The valve 72 is urged out of the expanded end 74 by the connector cables 84 which are connezLed to the upper r
I
r r rr r.
r rs ft' -v
LB
I*^fff L®
E
i 4 4.
extensions of the valve by releasable means 83. Once outside of the expanded end 74, the valve 72 expands due to the natural resiliency of the valve and the connector cables. The valve delivery catheter 75 is then removed by withdrawing it through the inner lumen 40 of the occluding catheter 10. Alternatively, the valve 72 may be provided with a temporary or permanent expandable support frame. The frame may contain stapling elements to secure the valve to the aortic wall.
The Dacron skirt 73 is fixed to the aortic root 12 by means of a plurality of staples 76, as shown in Fig. 7, which are secured -by the stapling mechanism 77 which is advanced through the inner lumen and out of the distal port 41. The stapling mechanism 77 has an Lshaped holding arm 78 that holds the staple 76 and shaping member 79 having an arcuate shaping surface 80 which presses the staple 76 against holding arm 78 deforming the staple as it is pushed through the Dacron skirt 73 and into the aortic wall 81 as shown to force the pointed arms or tines thereof toward each other and fix the staple within the aortic wall. In the alternative the holding arm 78 may be moved toward the shaping member 79 or both may be advanced toward each other.
The stapling mechanism 77 is preferably provided with a removable protective sheath (not shown) to facilitate the advancement of the mechanism through the inner lumen 40 without the pointed ends or tines of the staples 76 sticking into the inner wall of the occluding catheter which defines the inner lumen 40. Usually about 10 to about 20 staples will be required to adequately secure the skirt 73 to the aortic wall 81.
The angioscope 67 is provided to allow the physician to observe the I ei r rr Ir
I
3 ~a"ee~p~sP~B~P~B 1
I:
A
22 procedure and guide the stapling mechanism 77 to the desired location and to secure the staple 76 and the skirt 73 at the desired location within the aortic root 12.
SOnce the Dacron skirt 73 is properly secured, the inverted valve 72 isipulled through the fixed Dacron skirt 73, as shown in Fig. 8, and the upper extensions of the new valve 72 are stapled in essentially the same manner as the Dacron skirt 73. Care must be exercised when placing the Dacron skirt 73 prior to securing it to the aortic wall 81 so that when the inverted portion of the new valve 72 is pulled through the secured Dacron skirt 73, the ostia 52 and 53 of the coronary arteries 50 and 51 are not blocked by the upper extensions 82 of the valve 72. After the upper extensions 82 are secured to the aortic Swall 81, the releasable means 83 at the end of the connector cables 84 are released and the cables are withdrawn through the inner lumen 40 of 15 the occluding catheter S" Any tissue debris resulting from the aortic valve removal and new valve placement is trapped by the barrier formed by the inflated balloon 11 on the distal end of the occluding catheter However, liquid in the aortic region containing such debris may be removed through an aspiration tube (not shown) disposed within the inner lumen 40 of the occluding catheter 10 or through inner lumen 40 by aspirating the fluid containing the debris. An irrigation catheter may be used to dislodge any debris caught between the inflated balloon 11 and the aortic wall where the two meet.
1 :_i r-.
~c.
;:a
II;
ci.: i;
P
Z ti i i When the replacement valve 72 is secured in place, the fluid pumped through the retroperfusion catheter 20 is changed to a compatible fluid, e.g. saline or blood, containing no cardioplegic agents in order to flush out the cardioplegic materials from the myocardium through the ostia 52 and 53. The pulmonary venting catheter 54 may also be removed at the same time. Shortly thereafter the heart begins to beat on its own or it is externally defibrillated and the blood coming into the right heart is pumped through the pulmonary trunk to the lungs where it is oxygenated in the normal fashion. Oxygenated blood is returned from the lungs into the left atrium and is then pumped from the left ventricle through the new valve into the ascending aorta. Initially, the balloon 11 is maintained in the inflated condition, forcing the blood pumped out of the left ventricle to pass through the region of the ascending aorta 12 into inner lumen 40 of the occluding catheter 10 taking with it debris, emboli and the like. The blood passing through inner lumen 40 is directed through the third arm 32 of adapter 26, through the:valve 34 and line 36 leading to blood filter and recovery unit 37 where the blood may be -filtered and returned to the patient through the cardiopulmonary by-pass system 18. Alternatively, the position of thervalve 34 may be changed by means of arm 85 to discharge blood or other fluid containing tissue, emboli, debris and the like through discharge line 35. After sufficient time has elapsed to ensure that debris and embolus free oxygenated blood is being pumped out of the left ventricle 13 the balloon 11 is deflated to allow natural blood flow through the aorta and the cardiopulmonary by-pass system 18 is shut down.
-y
J
i i Ir.
r f~ -i;B -tJ~ irra irr i:: r
~C
II;
rre ir r
.I
r Ir~ w e:i f i:L .f! The occluding catheter shaft 39 may be formed of conventional materials such as polyethylene, polyvinyl chloride and the like. Balloon 11 may be formed of materials such as latex, silicone, C- Flex, or the like. Preferably, the balloon 11 is elastic, so as to expand to and circumferentially occlude the vessel into which it is positioned when fluid pressure is applied to the balloon. Alternatively, the balloon 11 may be formed of polymers such as polyethylene, polyethylene teraphthalate, or a polyolefinic ionomer such as Surlyn®, which is available from E.I.
DuPont, DeNemours Co. Such a balloon would be relatively inelastic when inflated, so as to inflate to a predetermined size and maintain essentially that size even when additional fluid pressure is applied within the interior of the balloon. The balloon 11 will generally have an expanded diameter of about 20 to 40 mm to effectively occlude the patient's ascending aorta and an expanded length of about 2 to about 15 cm so as to be disposed between the coronary ostia and the brachiocephalic artery without blocking these arteries. The overall length of the occluding catheter should be at least 80 cm to facilitate passage through the femoral or brachiocephalic arteries to the ascending aorta.
The retroperfusion catheter 20 may be a commercially 20 available retroperfusion catheter. There are suitable cardiopulmonary bypass systems available commercially. For a brief discussion of cardiopulmonary by-pass systems reference is made to Weber, John G., Encyclopedia of Medical Devices and Instrumentation, Vol. 3, pp. 1440- 1457.
I,
I; f 1:' 1~
F--
II-Pi a~ IIIP
~UC~D
An alternative tissue cutting system is depicted in Figs. 9 and 10. In this embodiment catheter 90 is provided with a cutting head 91 which is slidably disposed within the cutter housing 92.
The cutting head 91 is provided with a cutting edge 93 and cutter housing 92 is provided with cutting edge 94. The distal end of the catheter 90 is urged against tissue which is to be removed so that the I tissue is pressed into the receiving chamber 95 within the cutting head 91. The cutting head 91 is slidably withdrawn from the cutter housing 92 so that the cutting edge 93 slides by the cutting edge 94 in a cutting relationship so as to sever the tissue within the receiving chamber The severed tissue may be removed by aspiration or the cutting head 91 may be withdrawn from the patient and the severed tissue may be manually or otherwise removed. Preferably, the positioning of the distal S end of catheter 90 and the urging of the cutting head against the tissue :15 to be removed is observed by the physician or other operator through
S.
r angioscope 67 or other suitable imaging system as previously described.
Another cutting system 96, which is shown in Fig.
Io 11, has expandable cutting blades 97 and 98 which are biased or Sotherwise adapted to expand to a cutting position as shown and rotated 20 at high rotational speeds by a drive shaft and then pressed against the tissue to be severed. The blades 97 and 98 may be biased to expand outwardly by a spring (not shown) or the blades may be forced outwardly -H by the high speed rotation thereof. This cutting operation is likewise preferably observed by the physician or other operator to ensure proper S 25 cutting of the tissue to be removed.
1* fii.
26 An alternative valve introducer device 100 is shown in Figs. 12-13 which is adapted to contain a prosthetic or replacement valve 101 within expanded distal portion 102. The introducer device 100 may be introduced by itself or through the inner lumen of the occluding delivery catheter such as previously described until the enlarged distal portion 102 is located at or extends out of the distal end of the delivery catheter. The valve introducer device 100 may be provided with one or more positioning balloons 103 surrounding the expanded distal end 102 thereof which may be inflated in a differential manner, to assure accurate positioning of a prosthetic valve 101 when delivered out of the expanded distal end. A means, such as piston 104 is provided to push the replacement valve 101 out of the expanded distal end 102 when it is in the appropriate position within the patient's ascending aorta. Forceps or other holding means as previously described may be used to position the 15 replacement valve 101 within the location from which the original valve has been removed.
I An alternative replacement or prosthetic valve 101 is best shown in the expanded condition in Figs. 14 and 15. As indicated, the valve 101 is provided with a cylindrical base 105 having mounting staples 106 which can be pressed into the wall portion of theascending aorta at the desired situs by means of an expandable inelastic balloon 107 which is inflated within the valve 101. The upper extensions 108 of the replacement valve 101 rom which the leaves or cusps 109 are supported ar or the most part self supporting and may not require 2 25 securing to the wall section of the ascending aorta. The valve introducer
S.
-4i 27 device 100 and the inflatable balloon 107 which when inflated presses the mounting staples 106 into the aortic wall may, when deflated, be withdrawn through the inner lumen of a delivery catheter. The aortic region between the site of the replacement valve and the delivery catheter may be well irrigated to remove debris, emboli and the like before regular blood flow through the region is resumed.
The invention provides several benefits, including the ability to endovascularly replace existing cardiac valves or perform other cardiac procedures while avoiding the riskier, more expensive and more traumatic open-heart surgical procedure.
The replacement prosthetic valve device is preferably a bioprosthetic device because these valves do not require the patient to undertake life-long anticoagulant therapy as do mechanical valves. Once Sinserted, the bioprosthetic valve is capable of operating autonomously.
i5 The useful life of a bioprosthetic valve placed via the endovascular procedure may extend to over twenty years, and since most of the valve procedures are performed on the elderly, the bioprosthetic valve will usually function well throughout the remaining life of the patient.
Once the endovascular implantation of the prosthetic i 2T0 valve device is completed in the patient, the function of the prosthetic Svalve device can be monitored by the same methods as used to monitor c valve replacements done by open-heart surgery. Routine physical Sexamination, angiography, or periodic echocardiography can be performed. In contrast to open-heart surgery, however, the patient will recover in a very short period when his or her aortic valve is 5 p 28 endovascularly removed and replaced with a prosthetic valve. The replacement valve device can be used in any patient where bioprosthetic valves are indicated, and is particularly suitable for elderly patients and patients unable to tolerate open-heart procedures or life-long anticoagulation.
Unless described otherwise, The various components of the system of the present invention can be formed of conventional materials using conventional manufacturing techniques. The dimensions of the various components are selected so that they perform their intended functions in their intended environment.
While the present invention has been described herein in terms of certain preferred embodiments, it will be apparent to one of ordinary skill in the art that many modifications and improvements can be ll, ~made to the invention without departing from the scope thereof.
-rL I -y V i: i I a

Claims (6)

1. A system introducing a replacement valve comprising: a replacement valve having a portion which inverts from a first position to a second position, the replacement valve permitting flow in a direction and preventing flow in the other direction when in the second position; a valve delivery device for delivering the replacement valve, the replacement valve being mounted to the valve delivery device in the first position, the replacement valve being inverted from the first position to the second position after introduction into the patient.
2. The system of claim 1, further comprising: a valve securing device passing through and being slidably received by the valve delivery device.
3. The system of claim 3, wherein: the valve securing device is a stapler configured to drive staples through the replacement valve to secure the replacement valve.
4. The system of claim 1, wherein: the valve delivery device has a balloon sized to occlude the ascending aorta, the balloon having a diameter of about 20 to The system of claim 1, further comprising: a plurality of elongate members coupled to the portion of the replacement valve which everts, the plurality of elongate members being manipulated to evert the portion of the replacement valve from the first position to the second position.
6. The system of claim 1, wherein: the valve delivery device has a lumen, the lumen being coupled to a source of 25 cardioplegic fluid which is used to stop the patient's heart.
7. A system introducing a replacement valve, substantially as hereinbefore described with reference to Figures 6 through 8 of the accompanying drawings. co~ r rr cc I o o isoi o oLa rrr b r ~C EO~ 1 i Dated 28 January, 1999 Heartport, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON .1 j 7 I
AU14284/99A 1993-12-17 1999-01-29 System for cardiac procedures Expired AU714807B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14284/99A AU714807B2 (en) 1993-12-17 1999-01-29 System for cardiac procedures

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU699189 1993-12-17
AU60491/94A AU699189B2 (en) 1993-12-17 1993-12-17 System for cardiac procedures
AU14284/99A AU714807B2 (en) 1993-12-17 1999-01-29 System for cardiac procedures

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU60491/94A Division AU699189B2 (en) 1993-12-17 1993-12-17 System for cardiac procedures

Publications (2)

Publication Number Publication Date
AU1428499A true AU1428499A (en) 1999-04-01
AU714807B2 AU714807B2 (en) 2000-01-13

Family

ID=3745559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14284/99A Expired AU714807B2 (en) 1993-12-17 1999-01-29 System for cardiac procedures

Country Status (1)

Country Link
AU (1) AU714807B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011469A (en) * 1988-08-29 1991-04-30 Shiley, Inc. Peripheral cardiopulmonary bypass and coronary reperfusion system
US5092872A (en) * 1989-07-28 1992-03-03 Jacob Segalowitz Valvulotome catheter
US5295958A (en) * 1991-04-04 1994-03-22 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification

Also Published As

Publication number Publication date
AU714807B2 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
AU699189B2 (en) System for cardiac procedures
AU709259B2 (en) Retrograde delivery catheter and method for inducing cardioplegic arrest
US6866650B2 (en) System for cardiac procedures
US5702368A (en) System for cardiac procedures
US5458574A (en) System for performing a cardiac procedure
US5769812A (en) System for cardiac procedures
US6579259B2 (en) Endovacular cardiac venting catheter and method
US5713951A (en) Thoracoscopic valve prosthesis delivery device
US6899704B2 (en) Devices and methods for intracardiac procedures
US5814097A (en) Devices and methods for intracardiac procedures
JPH06511167A (en) endovascular aortic valve replacement
AU714807B2 (en) System for cardiac procedures
AU2002300155B2 (en) Endovascular cardiac venting catheter and method

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)